An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

NCT ID: NCT05276830

Last Updated: 2023-08-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-08
• Study Completion Date: 2022-04-01

Brief Summary

A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation associated with all forms of dementia (i.e., probably Alzheimer's Disease, vascular dementia; mixed; frontotemporal dementia) excluding Parkinson's-Related Dementia and Lewy Body Dementia.

Detailed Description

The study will enroll at least 75 subjects to receive a single film consisting of BXCL501 40 μg dose, BXCL501 60 μg dose, or matching placebo film. Subjects must reside in a residential care facility and must require at least moderate assistance with activities of daily living (e.g., bathing, dressing, and toileting). The subject must be able to self-administer the film to participate in the study.

The effects of BXCL 501 on acute agitation will be assessed by the following scales: PEC, PAS, ACES, and CGI-I.

Conditions

Agitation; Dementia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

40 micrograms

Sublingual film containing 40 micrograms Dexmedetomidine

Group Type: EXPERIMENTAL

BXCL501

Intervention Type: DRUG

Sublingual film containing 40 Micrograms BXCL501

60 micrograms

Sublingual film containing 60 micrograms Dexmedetomidine

Group Type: EXPERIMENTAL

BXCL501

Intervention Type: DRUG

Sublingual film containing 60 Micrograms BXCL501

Placebo

Sublingual Placebo film

Group Type: EXPERIMENTAL

Placebo film

Intervention Type: DRUG

Matching Sublingual Placebo film

Interventions

BXCL501

Sublingual film containing 40 Micrograms BXCL501

Intervention Type: DRUG

BXCL501

Sublingual film containing 60 Micrograms BXCL501

Intervention Type: DRUG

Placebo film

Matching Sublingual Placebo film

Intervention Type: DRUG

Other Intervention Names

Dexmedetomidine; Dexmedetomidine; Placebo

Eligibility Criteria

Inclusion Criteria

1. Individuals diagnosed with any form of dementia (i.e., probable Alzheimer's Disease; vascular dementia; mixed; frontotemporal dementia)

2. Subjects who have met DSM-5 criteria for dementia (major neurocognitive disorder) who have instances of acute psychomotor agitation.

3. History of psychomotor agitation (e.g., kick, bite, flailing) to the point that it impairs social activities, requires staffing, or medical intervention, or impairs ability for functional activities of daily living.

4. Subjects are expected to exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior.

5. Subjects who have a score of ≤16 on the Mini-Mental State Exam (MMSE).

6. Subjects with a remote (>5 years) history of stroke may be included, regardless of size/location.

7. Subjects who read, understand, and provide written informed consent, or who have a legally authorized representative (LAR).

8. Subjects who are deemed to be medically appropriate for study participation by the principal investigator.

9. Subjects who are at their current location for at least 14 days before screening and plan to remain at the same location for the duration of the study.

10. Subjects who have the capability to participate in the study and self-administer the investigational product.

11. Subjects who are on a stable concomitant medications regimen for the treatment of any concurrent conditions for at least one month prior to the screening visit.

Exclusion Criteria

1. Subjects who have dementia associated with Parkinson's disease and/or Lewy Body Disease are excluded.

2. Subjects suffering from alcohol and/or substance abuse.

3. Subjects with agitation caused by acute intoxication must be excluded.

4. Subjects with significant risk of suicide or homicide per the investigator's assessment.

5. Subjects who have hydrocephalus, seizure disorder, or history of significant head trauma, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, or focal neurological findings, with a recent (1 year) large (non-microvascular) stroke who may be considered medically unstable or in recovery must be excluded.

6. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years.

7. Subjects with laboratory or ECG abnormalities.

8. Subjects with serious, unstable, or uncontrolled medical illnesses must be excluded.

9. Subjects who have received an investigational drug within 30 days prior to Screening must be excluded.

10. Subjects who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving dexmedetomidine must be excluded.

11. Subjects whose agitation is attributed to pain or infection, delirium, concomitant medications, environmental conditions, or another psychiatric condition or medical condition as determined by the investigator.

• Minimum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cognitive Research Corporation

INDUSTRY

Sponsor Role: collaborator

BioXcel Therapeutics Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert Risinger, MD

Role: STUDY_CHAIR

BioXcel Therapeutics

Locations

Bioxcel Clinical Research Site

North Miami, Florida, United States

Bioxcel Clinical Research Site

Springfield, Massachusetts, United States

BioXcel Clinical Research Site

Toms River, New Jersey, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

BXCL501-203

Identifier Type: -

Identifier Source: org_study_id